By MDose AI · Montréal and Québec

From assessment to action plan.

MDose AI offers software, AI, audit and validation in pharmaceutical settings. Solutions MDose inc. is not a pharmacy and offers no pharmaceutical services: the responsible pharmacist keeps all clinical decisions and approves what will be used.

Bill 67 readiness

A clearly scoped engagement.

You receive a written plan, templates and a register, not a guarantee of compliance. A fixed price is set after a first conversation, based on the number of branches, never on prescription or service volume.

01

Guided assessment

A review of your answers with your team, branch by branch, to separate what is ready from what is not yet.

02

Plan by service

For each activity: offer, phase in or refer, with a lead, resources and a review date.

03

Procedures to approve

Draft procedures and working templates, which the responsible pharmacist still has to review and approve.

04

AI readiness

An inventory of your tools, their uses and risks, questions to ask vendors and a use policy for your team.

05

Privacy and Law 25

Support with privacy impact assessments for your digital tools and vendors.

06

Audit and validation

A clear reading of your systems and integrations, with tests and traceable evidence when the use warrants it.

MDose tools

Tools in service of the professional.

None of them decides for the professional. Check each tool’s status before adopting it.

AI readiness

Adopting AI without delegating judgment.

AI can help draft, transcribe and summarize. It does not replace the pharmacist’s assessment, and the professional remains responsible for what goes into the file.

To our knowledge, the Ordre has not published a specific rule on AI, but professional duties and privacy laws still apply. In September 2026, Canada’s privacy commissioners also adopted a joint resolution on AI in health.

  • Which tools are used, by whom and for which tasks, including unauthorized uses
  • What personal information they process, where it is hosted and whether it is used for training
  • Who checks the result before it is used, and how to challenge it
  • What privacy impact assessment is required before adoption
  • What the vendor contract says about use, retention, audit and confidentiality
  • What to do in the case of a decision based exclusively on automated processing
  • For AI transcription: the vendor’s certification and patient consent

Sources: Joint resolution of Canada’s privacy commissioners on AI in health, September 15, 2026 · CAI, joint resolution on AI in health, October 29, 2026 (in French) · CAI, main changes under Law 25 (in French) · Québec.ca, AI transcription (in French) · OPQ and A.P.E.S., podcast on AI in pharmacy (in French)

Talk to us

Stay in touch.

Receive important updates on Bill 67, or ask us to contact you about support or the pilot program.

Prefer to write directly? See our email address.

What interests you
Do not enter any patient information.